SCHEMBL4637952

SCHEMBL4637952

N#Cc1ncn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1I

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.35
CYP19A1 P11511 1/20 0.35
UGT1A4 P22310 1/20 0.35
PDE4D Q08499 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
JUN P05412 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
TSHR P16473 1/20 0.33
CASP1 P29466 1/20 0.32
CASP5 P51878 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4639433 0.83 SMN1; SMN2 (0.36) CYP19A1UGT1A4PDE4DL3MBTL1JUN
SCHEMBL4639418 0.74 GRIN2B (0.40) KDM4ESMN1; SMN2CYP3A4CYP2D6
SCHEMBL11484298 0.72 ROCK2 (0.44) L3MBTL1KDM4ESMN1; SMN2ALDH1A1CTSK
SCHEMBL11485624 0.70 QPCT (0.39) L3MBTL1KDM4ESMN1; SMN2ALDH1A1QPCT
SCHEMBL1301329 0.65 POLB (0.39) PDE4DHTTSMN1; SMN2MEN1KMT2A
SCHEMBL11484822 0.64 CYP11B1 (0.38) CYP19A1ALDH1A1IDO1QPCT
SCHEMBL4638004 0.63 ALDH1A1 (0.42) KDM4EHTTSMN1; SMN2MEN1ALDH1A1
SCHEMBL31144859 0.62 XPO1 (0.36) CTSK
SCHEMBL23464140 0.62 CYP19A1 (0.33) CYP19A1UGT1A4PDE4DCTSK
SCHEMBL11484357 0.62 TOP2A (0.38) CYP19A1L3MBTL1KDM4EHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501808-B1 TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-07-02 EP disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 CDK1 2092/4885CYP19A1 2765/4885UGT1A4 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.